Sugi Predict

Sugi Predict / Targets / NTRK2

NTRK2

BDNF/NT-3 growth factors receptor · Q16620 · NTRK2 on Sugi Atlas →

89,847 patent compounds predicted against NTRK2, 60,768 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL57964 SCHEMBL57964 0.47 4/20
SCHEMBL60419 SCHEMBL60419 0.43 4/20
Linifanib Linifanib (SCHEMBL93804) 1.00 3/20
SCHEMBL102639 SCHEMBL102639 0.65 3/20
SCHEMBL58313 SCHEMBL58313 0.59 3/20
SCHEMBL58543 SCHEMBL58543 0.57 3/20
SCHEMBL60464 SCHEMBL60464 0.57 3/20
SCHEMBL58550 SCHEMBL58550 0.55 3/20
SCHEMBL59884 SCHEMBL59884 0.54 3/20
SCHEMBL65790 SCHEMBL65790 0.52 3/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL58421) 0.52 3/20
SCHEMBL58416 SCHEMBL58416 0.50 3/20
SCHEMBL59547 SCHEMBL59547 0.49 3/20
SCHEMBL90887 SCHEMBL90887 0.49 3/20
SCHEMBL90935 SCHEMBL90935 0.49 3/20
SCHEMBL59451 SCHEMBL59451 0.49 3/20
SCHEMBL100329 SCHEMBL100329 0.49 3/20
SCHEMBL60289 SCHEMBL60289 0.48 3/20
SCHEMBL100040 SCHEMBL100040 0.48 3/20
SCHEMBL100903 SCHEMBL100903 0.47 3/20

Clinical trials — most relevant to NTRK2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of Oxcarbazepine on Serum Brain Derived Neurotrophic Factor (BDNF) in Bipolar Disorder PHASE4COMPLETED
Comparison of Antidepressant Augmentation With Amantadine vs Pramipexole vs Quetiapine in Treatment Resistant Depression PHASE4UNKNOWN
Does TMS Affect Neuroplasticity? The Role of Brain-derived Neurotrophic Factor and Neuronal Cell Adhesion Molecules - an Intensive Clinical Protocol Among Patients With Obsessive-compulsive Disorders PHASE4COMPLETED
Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation PHASE4COMPLETED
Study to Assess Safety and Efficacy of Fingolimod in Children With Rett Syndrome PHASE1/PHASE2COMPLETED
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG) PHASE2ACTIVE_NOT_RECRUITING
Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease PHASE2COMPLETED
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors PHASE2RECRUITING
Cilostazol in Parkinson's Disease PHASE2NOT_YET_RECRUITING
Psychoneuromentalism Disorder: A Medical Condition That Affects People With Psychological Impairments From Health Issues EARLY_PHASE1NOT_YET_RECRUITING
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors nanACTIVE_NOT_RECRUITING
A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib nanCOMPLETED
Regular Exercise Improves Physical Capacity and Promotes Neurotrophins in Patients With Multiple Sclerosis nanCOMPLETED
Effects of Exercise on Functional Performance, BDNF, Executive Functions and Sleep Quality in Children with Epilepsy nanNOT_YET_RECRUITING
Study of the Effect of Antidepressant Drugs on Neurotrophic Factors in Patients With Depression nanCOMPLETED
Anxiety and Depression Disorder in Patient Treated With rTPA for Mangment of Acute Ischemic Stroke nanUNKNOWN
Management of Deep Retinal Capillary Ischemia by Electromagnetic Stimulation and Platelet- Rich Plasma nanCOMPLETED
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study nanCOMPLETED
Genetic Predictors of Lithium Response in Bipolar Disorder nanCOMPLETED
Biomarkers in Blood and Tissue Samples From Patients With Newly Diagnosed Neuroblastoma nanCOMPLETED
Epigenetic Regulation of BDNF in Major Depression nanCOMPLETED
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury nanRECRUITING
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia nanRECRUITING
Investigating Neurocognitive, Motor and Biological Effects of MindLenses Professional in Neurological Diseases nanCOMPLETED
Effects of Genetic Variation on the Efficacy of Aerobic Exercise nanCOMPLETED
Association of Urine BDNF and NGF With Lower Urinary System Parameters nanRECRUITING
Predictors of Better Outcomes After Severe Acquired Brain Injuries nanUNKNOWN
IGF and Other Neurotrophic Factors in Patients With Dementia nanCOMPLETED
Molecular Markers of Neuroplasticity During Exercise in People With Incomplete Spinal Cord Injury nanCOMPLETED
Effect of Vitamin D Administration Along With SSRIs in Patients With Major Depressive Disorder nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a NTRK2 binder may also engage these)

ProteinNameSimilarity
Q63604 — 1.000 Q63604 →
P15209 — 1.000 P15209 →
Q91044 — 0.998 Q91044 →
P24786 — 0.996 P24786 →
Q5IS37 — 0.994 Q5IS37 →
Q5IFJ9 — 0.993 Q5IFJ9 →
Q6VNS1 — 0.991 Q6VNS1 →
Q91987 — 0.990 Q91987 →
Q03351 — 0.990 Q03351 →
NTRK3 NT-3 growth factor receptor 0.987 landscape →
Q01887 — 0.980 Q01887 →
Q5IS82 — 0.979 Q5IS82 →
ROR1 Inactive tyrosine-protein kinase transmembrane receptor ROR1 0.977 landscape →
P34925 — 0.975 P34925 →
Q91009 — 0.974 Q91009 →
Q9Z139 — 0.972 Q9Z139 →
P38438 — 0.971 P38438 →
P11273 — 0.971 P11273 →
Q90999 — 0.971 Q90999 →
TGFBR2 TGF-beta receptor type-2 0.969 landscape →
Q8BXA0 — 0.968 Q8BXA0 →
Q5GIG6 — 0.968 Q5GIG6 →
Q62312 — 0.967 Q62312 →
PRKD1 Serine/threonine-protein kinase D1 0.966 landscape →
P00534 — 0.966 P00534 →
Q7TQP6 — 0.965 Q7TQP6 →
TNNI3K Serine/threonine-protein kinase TNNI3K 0.965 landscape →
Q5XIS9 — 0.964 Q5XIS9 →
Q8TDF5 — 0.963 Q8TDF5 →
D4A1J9 — 0.963 D4A1J9 →